Tag: opioid epidemic

Trump says death sentences for dealers will solve U.S. drug problem

Former President Donald Trump said soft sentences for drug dealers have helped fuel fentanyl overdose deaths in the U.S.

Trump, 77, is running against President Joe Biden in the presidential election this November.

“So many are dying where they think they’re getting something and going to have a little fun on a Friday night and all of sudden their dead,” Trump said on Fox News.

“You’ll never really solve the drug problem unless you do what other countries do – and that’s the death penalty for drug dealers,” Trump said during the interview. “A drug dealer on average will kill, during that person’s life, 500 people. Unless you have a death penalty. Right now, they don’t even get charged with anything.”

Thirty-four countries apply the death for some drug crimes, according to a 2023 report from Harm Reduction International. The report noted that Pakistan removed the death penalty as a possible punishment for certain violations of its Control of Narcotics Substances Act.

Illicit fentanyl killed nearly 38,000 Americans in the first six months of 2023, according to a 2024 DEA report. Synthetic opioids were involved in 74,225 deaths in 2022 – 68% of the total 111,036 deaths that year, according to the Centers for Disease Control and Prevention.

Keep reading

Biden admin backs ‘harm reduction groups’ that give free drug paraphernalia to addicts

President Biden and his administration have expressed support for providing free drug paraphernalia to fentanyl and other illicit drug users, an effort made feasible by controversial harm reduction groups that believe supplying addicts with clean smoking gear would reduce overdose deaths by eliminating injection methods.

However, a study released in February by the Centers for Disease Control and Prevention (CDC) revealed that smoking fentanyl was increasingly linked to overdose deaths in 27 states and Washington, DC. Researchers found that 74 percent of overdose deaths were linked to smoking fentanyl, while fentanyl overdose deaths through injection plummeted.

The Washington Post reported that the Biden administration has embraced the approach of harm reduction groups, despite the fact that these groups have received widespread criticism, and their efforts, which have failed to create significant positive outcomes, have been banned in numerous jurisdictions.

Critics of harm reduction groups believe supplying addicts with free drug paraphernalia only enables their addictions, and think alternative methods such as rehabilitation and therapy are better options. Those who favor harm reduction measures believe that providing clean drug equipment to users, such as smoke pipes and needles, and creating so-called “safe injection sites,” would prevent overdose deaths and the spread of infections caused by sharing needles. However, their methods have been proven as failed experiments.

Keep reading

Marijuana Terpenes Are ‘As Effective As Morphine’ For Pain Relief And Have Fewer Side Effects, New Study Finds

A new federally funded study into the effects of cannabis terpenes suggests that the compounds could be “potential therapeutics for chronic neuropathic pain,” finding that an injected dose of the compounds produced a “roughly equal” reduction in pain markers when compared to a smaller dose of morphine. Terpenes also appeared to enhance the efficacy of morphine when given in combination.

Unlike with morphine, however, none of the studied terpenes produced a meaningful reward response, the research found, indicating that “terpenes could be effective analgesics with no rewarding or dysphoric side effects.”

Notably, terpenes that were vaporized or administered orally seemed to have little impact on pain.

The paper, “Terpenes from Cannabis sativa induce antinociception in a mouse model of chronic neuropathic pain via activation of adenosine A2A receptors,” was published this month in PAIN, the journal of the International Association for the Study of Pain. The 14-author team behind the report includes researchers from the University of Arizona’s Comprehensive Center for Pain and Addiction as well as the National Institutes of Health (NIH).

“A question that we’ve been very interested in is could terpenes be used to manage chronic pain?” lead researcher John Streicher, a professor of pharmacology at the University of Arizona’s College of Medicine in Tucson, said in a press release about the study. “What we found is that terpenes are really good at relieving a specific type of chronic pain with side effects that are low and manageable.”

Authors note that while primary chemical components in marijuana, like THC and CBD, have been shown in some studies to be effective in managing chronic pain, “their efficacy is generally moderate, and THC is burdened by unwanted psychoactive side effects.”

“These limits have focused attention on other potentially therapeutic components of Cannabis,” they wrote, “including minor cannabinoids, flavonoids, and terpenes.”

Keep reading

Fentanyl Fear Factor: White House Leverages Drug Scare to Push for Controversial Surveillance Powers

In a recent public appeal, the Biden administration has urged the reauthorization Section 702 of the Foreign Intelligence Surveillance Act (FISA) before it expires on April 19. Bill Burns, the CIA Director, issued a statement, alleging the significant role of the FISA powers in fighting threats against national security, especially the illicit trafficking of fentanyl into the United States.

Burns highlighted the gravity of the fentanyl threat, saying, “The threat to the US posed by fentanyl and other synthetic opioids is real. Section 702 is an essential tool in CIA’s mission to protect the American people from a range of threats, including illicit fentanyl trafficking. Without this vital program, CIA simply would not be able to defend our country as effectively in as many dangerous corners of the world.”

Echoing the CIA Director’s stance, the White House has also underlined the importance of the reauthorization bill in ensuring national security. National Security Communications Advisor John Kirby further stressed the significance of bipartisan support for this endeavor. He stated, “Obviously we strongly support the bipartisan effort to get 702 reauthorized. It is vital to our ability to defend ourselves, defend … the American people, and we very much want to see it move forward — get extended and move forward.”

It’s worth noting that Section 702 of FISA authorizes US government officials to collect electronic communications without needing a warrant. This provision has been a point of contention, with privacy advocates arguing that it infringes on personal freedom.

Keep reading

CIA Wants Congress to Expand Top-Secret Eavesdropping Program To ‘Fight Against Fentanyl Crisis’

The Central Intelligence Agency (CIA), along with other members of the U.S. intelligence community, are pushing for Congress to expand Section 702 of the Foreign Intelligence Surveillance Act of 1978 in order to fight the ongoing fentanyl crisis.

According to the Brennan Center of Justice, Section 702, “Authorizes the government to collect the communications of non-Americans located abroad without a warrant from a court. While this surveillance is supposed to target foreigners, it inevitably sweeps in Americans’ private phone calls, emails, and text messages too.”

USA Today has reported that top CIA officials spent most of 2023-2024 urging members of Congress to reauthorize Section 702 of the FISA Act of 1978.

However, CIA officials believe in its current form, Section 702 limits the intelligence community from targeting everyone involved in the fentanyl trade overseas and are advocating lawmakers to expand Section 702 so U.S. spies will have more liberty when it comes to going after criminals engaged in the fentanyl trade.

Many lawmakers are skeptical of expanding Section 702 due to the CIA previously misusing the law to spy on American citizens.

Keep reading

The War on Drugs Is Also a War on Pain Patients

In a March 22 opinion column in the New York Times entitled “The DEA Needs to Stay Out of Medicine,” Vanderbilt University Medical Center associate professor of anesthesiology and pain management Shravani Durbhakula, MD, documents powerfully how patients suffering from severe pain—many of them terminal cancer patients—have become collateral casualties in the government’s war on drugs.

Decrying the Drug Enforcement Administration’s progressive tightening of opioid manufacturing quotas, Dr. Durbhakula writes:

In theory, fewer opioids sold means fewer inappropriate scripts filled, which should curb the diversion of prescription opioids for illicit purposes and decrease overdose deaths — right?

I can tell you from the front lines that that’s not quite right. Prescription opioids once drove the opioid crisis. But in recent years opioid prescriptions have significantly fallen, while overdose deaths have been at a record high. America’s new wave of fatalities is largely a result of the illicit market, specifically illicit fentanyl. And as production cuts contribute to the reduction of the already strained supply of legal, regulated prescription opioids, drug shortages stand to affect the more than 50 million people suffering from chronic pain in more ways than at the pharmacy counter.

Dr. Durbhakula provides stories of patients having to travel long distances to see their doctors in person due to DEA requirements about opioid prescriptions. However, despite their efforts, they find that many of the pharmacies do not have the opioids they require because of quotas. She writes:

Health care professionals and pharmacies in this country are chained by the Drug Enforcement Administration. Our patients’ stress is the result not of an orchestrated set of practice guidelines or a comprehensive clinical policy but rather of one government agency’s crude, broad‐​stroke technique to mitigate a public health crisis through manufacturing limits — the gradual and repeated rationing of how much opioids can be produced by legitimate entities.

In the essay, Dr.Durbhakula does not question or challenge the false narrative that the overdose crisis originated with doctors “overprescribing” opioids to their pain patients.

Keep reading

Activists Renew Effort To Use Opioid Settlement Funds To Study Ibogaine For Addiction In Ohio After Kentucky Plan Falls Through

Psychedelic medicine proponents are redirecting their efforts to use millions in opioid-related state settlement money for ibogaine research from Kentucky to Ohio.

The original plan to use $42 million from Kentucky’s opioid settlement fund for psychedelics research fell through late last year after the state’s new attorney general replaced then-Kentucky Opioid Commission Chairman Bryan Hubbard, who was spearheading the ibogaine initiative, with a former Drug Enforcement Administration (DEA) official.

Now Hubbard has joined ResultsOHIO, a division of the Ohio Treasurer’s Office, where he will be partnering with the Reaching Everyone in Distress (REID) Foundation in hopes of securing a portion of that state’s opioid settlement funds to promote psychedelics clinical trials for substance misuse treatment.

“I’m honored to work with the REID Foundation and the people of Ohio to bring hope and healing to veterans and families being torn apart by the opioid crisis,” Hubbard said in a press release. “The development of ibogaine as a treatment option for opioid-dependent individuals is a moral imperative.”

A Kentucky commission focused on opioid overdose abatement held several meetings last year to go over the ibogaine initiative that’s since fizzled out in that state under the new attorney general. Members heard testimony from military veterans, parents, psychologists and other advocates—including former Texas Gov. Rick Perry (R)—about the therapeutic potential of the psychedelic.

Like Kentucky, Ohio has been hard hit by the opioid overdose crisis. And under the settlement agreement, the state is expected to receive about $1 billion that could be used for various programs and services to help mitigate the public health issue.

The plan for the ibogaine effort is to seek funding for the research through a public-private partnership, while also exploring the creation of a specific program under ResultsOHIO to facilitate the partial settlement distribution, Psychedelic Alpha reported.

Keep reading

Did Decriminalization Boost Drug Deaths in Oregon?

Oregon is considering legislation that would recriminalize low-level drug possession, reversing a landmark reform that voters approved in 2020. Although critics of that ballot initiative, Measure 110, cite escalating drug-related deaths, decriminalization is not responsible for that trend.

Opioid overdose fatalities have been rising nationwide for more than two decades. That trend was accelerated by the emergence of illicit fentanyl as a heroin booster and substitute, a development that hit Western states after it was apparent in other parts of the country.

“Overdose mortality rates started climbing in [the] Northeast, South, and Midwest in 2014 as the percent of deaths related to fentanyl increased,” RTI International epidemiologist Alex H. Kral and his colleagues noted at a conference in Salem, Oregon, last month. “Overdose mortality rates in Western states did not start rising until 2020, during COVID and a year after the introduction of fentanyl.”

That lag explains why Oregon has seen a sharper rise in opioid-related deaths than most of the country since 2020. But so have California, Nevada, and Washington, neighboring states where drug possession remains a crime.

Decriminalization under Measure 110 took effect in February 2021, and a 2023 Journal of Health Economics study estimated that it was associated with a 23 percent increase in “unintentional drug overdose deaths” that year. But “after adjusting for the rapid escalation of fentanyl,” Brown University public health researcher Brandon del Pozo reported at the Salem conference, “analysis found no association between [Measure 110] and fatal drug overdose rates.”

Kral and his collaborators concurred, saying “there is no evidence that increases in overdose mortality in Oregon are due to” decriminalization. That is consistent with the results of a 2023 JAMA Psychiatry study, which found “no evidence” that Measure 110 was “associated with changes in fatal drug overdose rates” during the first year.

Keep reading

Girlfriend charged with murder of former Texas judge who died of fentanyl overdose

Authorities in Texas have arrested the 35-year-old girlfriend of a former judge for allegedly supplying him with fentanyl that led to his overdose death late last year. Kami Ludwig was taken into custody on Monday and charged with the murder of 47-year-old former Associate Tarrant County Judge William Shane Nolen.

The murder charge is the result of a novel interpretation of a new law that Gov. Greg Abbott signed in June 2023 and went into effect on Sept. 1, 2023, classifying the supplying of fentanyl that results in death as murder. The law was enacted to combat the thousands of Texans who die annually from fentanyl poisoning, but appeared to primarily target drug dealers who distribute the deadly substance.

According to a news release from the Grapevine Police Department, officers at about 4:45 a.m. on Nov. 20, 2023, responded to a call regarding a deceased male — later identified as Nolen — at a residence located in the 4100 block of Mapleridge Drive. Ludwig placed the initial 911 call and identified herself to the dispatcher as Nolen’s girlfriend.

Upon arriving at the scene, first responders said they found Nolen deceased in his bedroom “with signs consistent with an opioid overdose.” Authorities on the scene said they also recovered “several” additional pills from inside the home.

Keep reading

Maine Democratic Governor And GOP Senate Leader Oppose Bill To Decriminalize Drugs And Invest In Treatment

Maine saw a reduction in the number of overdose deaths in 2023. But with hundreds upon hundreds of drug-related deaths last year, advocates and lawmakers say the state is still in the midst of a serious crisis.

In total, there were 607 confirmed or suspected overdose deaths in 2023, a 16 percent drop from the record total of 723 in 2022. Along with the 607 deaths, there were 9,047 confirmed nonfatal overdoses last year (compared to 9,760 in 2022).

“I think it’s hard to talk about this because that’s still 607 people who died last year and I don’t want to celebrate that whatsoever,” said Courtney Gary-Allen, organizing director of the Maine Recovery Advocacy Project. “That being said, there is a reduction, and I think we should be proud of the work that we’ve all collectively done on this issue.”

Gary-Allen cited investments in treatment by Gov. Janet Mills’ administration, the bipartisan consensus that substance use is a serious crisis that needs to be addressed, and the passage of the Good Samaritan law—which created enhanced protections from prosecution at the scene of an overdose to encourage people to call for help—as possible reasons for the reduction in deaths in 2023. Others have also cited the increased availability of the opioid overdose reversal naloxone.

Still, Gary-Allen said there is much more to do to address the overdose epidemic.

“I still have the faces in my head” of those who have died from drug overdoses, she said.

One proposal, backed by advocates in the recovery community and sponsored by Rep. Lydia Crafts (D-Newcastle), is to decriminalize the personal possession of illegal drugs and invest in an array of treatment options.

Supporters of the measure argue that criminalizing drug use pushes people into the shadows, making it harder for them to get help. Policing drug use and imprisoning people for substance use-related crimes also takes money away from a treatment-based approach, proponents of the bill say.

In all, policy analysts estimate the state could save around $45 million a year from not punishing people for possession of small amounts of drugs. Under the terms of the proposal, that money would then be invested into expanding what advocates say are often scant treatment options around the state.

Keep reading